Bjerkholt Eric's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Sep 12, 2023
- Accession no.
- 0001209191-23-049133
- Filed
- Sep 12, 2023
- Trade date
- Sep 11, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market purchases total $296.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bjerkholt EricCIK 0001197350 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2023 | Common Stock | PPurchaseAcquired | +10,000 | $29.65F1 | +$296,500 | 10,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2023 | Common Stock | AGrant or awardAcquired | +110,000 | $0.00 | $0 | 110,000 | Direct | |
| Sep 11, 2023 | Common Stock | AGrant or awardAcquired | +55,000 | $0.00 | $0 | 55,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported on this Form 4 is a weighted average price. The shares were purchased in multiple transactions ranging from $29.61 to $29.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.